GENETIC VARIANTS OF ADIPONECTIN AND THERAPEUTIC EFFICIENCY OF OMEGA-3 POLYUNSATURATED FATTY ACIDS IN PATIENTS TYPE 2 DIABETES MELLITUS
DOI:
https://doi.org/10.21856/j-PEP.2013.1.01Keywords:
type 2 diabetes mellitus, adiponectin gene polymorphism, omega-3 polyunsaturated fatty acids, therapyAbstract
In 61 type 2 diabetic patients it was defined single nucleotide polymorphism +276 G > T (rs1501299 ) in adiponectin gene and atherogenic potential dynamics (hormonal and metabolic parameters of insulin resistance, a pro-inflammatory state, oxidative status, adipokines) after daily administration for 12 weeks of omega-3 polyunsaturated fatty acids (Omacor) with the constant pattern of antidiabetic therapy. After the treatment, in all the surveyed it was revealed reduction of insulin resistance, while a significant increase in the levels of total adiponectin, total erythrocyte glutathione, as well as reduced levels of circulating insulin and osteoprotegerin were observed only in carriers of GG-genotype. These results suggest that genetic variations in the adiponectin gene can affect the therapeutic efficacy of omega-3 fatty acids, namely, to reduce the pattern of cardiovascular risk factors in type 2 diabetic patients in a Ukrainian population.
References
Hayden R, Tyagi SC. Cardiovascul Diabetol 2003; 2:1-10.
Gorshuns’ka MYu. Probl Endokryn Patologiyi 2012; 4:126-137.
Maeda N, Takahashi M, Funahashi T, et al. Diabetes 2001; 50:2094 — 2099.
Spiegelman BM, Flier JS. Cell 2001; 104(4):531-543.
Kershaw EE, Flier JS. J Clin Endocrinol Metabol 2004; 89:2548-2556.
Menzaghi C, Trischitta V, Doria A. Diabetes 2007; 56:1198-1209.
Ouchi N, Kihara S, Arita Y, et al. Circulation 1999; 100:2473-2476.
Ouchi N, Kihara S, Arita Y, et al. Circulation 2000; 102(11):1296-1301.
Arita Y, Kihara S, Ouchi N, et al. Biochem Biophys Res Commun 1999; 257(1):79-83.
Weyer C, Funahashi T, Tanaka S, et al. J Clin Endocrinol Metabol 2001; 86(5):1930-1935.
Gorshuns’ka MYu, Karachentsev YuI, Krasova NS, et al. Endokrynologiya 2007; 12(2):252-261.
Goldstein BJ, Scalia R. J Clin Endocrinol Metabol 2004; 89:2563-2568.
Itoh M, Suganami T, Satoh N, et al. Arterioscler Thromb Vasc. Biol 2007; 27:1918-1925.
Fernandez-Real JM, Vendrell J, Ricart W. Clin Chem 2005; 51:603-609.
Perez-Martinez P, Lopez-Miranda J, Cruz-Teno C, et al. J Nutr 2008; 38:609-614.
Iwaki M, Matsuda M, Maeda M, et al. Diabetes 2003; 52:1655-1663.
Karachentcev Y, Gorshunska M, Jansen E, et al. World Diabetes Congress, Dubai, 2011:458.
Comuzzie AG, Funahashi T, Sonnenberg G, et al. J Clin Endocrinol Metabol 2001; 86:4321-4325.
Gable DR, Matin J, Whittall R, et al. Ann Human Genetics 2007; 71: 453-466.
Matthews, DR, Hosker JP, Rudenski AS. Diabetologia 1985; 28: 412-419.
Katz A, Nambi SS, Mather K, et al. J Clin Endocrinol Metabol 2000; 85:2402-2410.
Reddy MN, Kumar K, Jamil K. J Mol Biomark Diagn 2012; 3:1-6.
Zhang J, Wu Y, Zhang Y, et al. Mol Endocrinol 2008; 22:1416-1426.
Kang ES, Park SY, Kim HJ, et al. Diabetes Care 2005; 28(5): 1139-1144.
Zhang H, Jia WP, Hu C, et al. Zhonghua Yi Xue Za Zhi 2007; 11: 2390-2393.
Secchiero P, Corallini F, Pandolfi A, et al. Am J Pathol 2006; 169(6): 2236-2244.
Simonet WS, Lacey DL, Dunstan CR, et al. Cell 1997; 89:309-319.
Olesen P, Ledet T, Rasmussen LM. Diabetologia 2005; 48:561-568.
Emery JG, McDonnell P, Burke MB, et al. J Biol Chem 1998; 273: 14363-14367.
Browner WS, Lui LY, Cummings SR. J Clin Endocrinol Metabol 2001; 86:631-637.
Kiechl S, Schett G, Wenning G, et al. Circulation 2004; 109:2175-2180.
Avignon A, Sultan A, Piot C, et al. Diabetes Care 2005; 28(9): 2176-2180.
Anand DV, Lahiri A, Lim E, et al. J Am Coll Cardiol 2006; 47(9): 1850-1857.
Reinhard H, Lajer M, Gall MA, et al. Diabetes Care 2010; 33(12): 2561-2566.
Sultan A, Avignon A, Galtier F, et al. Diabetes Care 2008; 31:593-595.
Fu M, Zhang J, Lin Yg, et al. Biochem Biophys Res Commun 2002; 294(3):597-601.
Lecka-Czernik B, Gubrij I, Moerman EJ, et al. J Cell Biochem 1999; 74(3):357-371.